Product Description
Mechanisms of Action: CAAP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Histogen
Company Location: San Diego CA 92121
Company CEO: Steven J. Mento
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Cholestasis|Liver Transplant|Hepatitis A|Hepatocellular Carcinoma|Hepatitis, Alcoholic|Liver Diseases, Alcoholic|Non-alcoholic Steatohepatitis|Fatty Liver, Alcoholic|Hepatitis|Liver Cirrhosis|Hypertension, Portal|Liver Cirrhosis, Alcoholic|Hepatitis, Chronic|Type 1 Diabetes|Hepatitis C, Chronic|Liver Failure, Acute|End Stage Liver Disease|Acute-On-Chronic Liver Failure|Hepatic Insufficiency
Phase 1: Intestinal Diseases|COVID-19|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
EMR-COV-PR001 | P1 |
Terminated |
COVID-19 |
2021-05-28 |
70% |
ENCORE-LF | P2 |
Unknown status |
Liver Cirrhosis |
2019-08-01 |
23% |
CON-EX-0217 | N/A |
Terminated |
Liver Cirrhosis |
2019-07-15 |
|
2015-004473-32 | P2 |
Completed |
Hypertension, Portal|Non-alcoholic Steatohepatitis|Liver Cirrhosis|Hepatitis, Alcoholic |
2019-04-08 |